New York City, despite its size, population and access to venture capital and top academic institutions, is not a major center for life science startups. But recent reports suggest that may—at least a little bit—be changing.
For example, Alexandria Real Estate Equities, which is a major developer of real estate for biopharma, is developing a 500,000-square-feet addition to its life science campus in Manhattan. Also, the Long Island City Partnership is working to develop a cluster of life science space in a Queens neighborhood, spurred on by the decision by Amazon to pull out of its HQ2 plans.
